Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

EOC cos bullsh*tters like you have been saying the same thing all the way down and been proved wrong time and time again.

How much you lost so far ???

Grow up son, the internet is full of people like you arguing behind a keyboard; bet in real life your a shortarse spotty git who wouldn't say boo to a mouse lol!

Go get a girlfriend or take up a constructive hobby.

My last reply so don't bother responding you immature little weasel.

So we agree that BPRG is a pile of sh*te then .

Nice recovery today, bodes well for the coming days.

Only 4 trading days till interims now, should get a run up to them.

Agree very nice recovery, though Dil will disagree. By the way is Dil short for Dildo?

It goes down , goes up , finishes all square does fcuk all and the local idiots are out celebrating.

u r really boring Dil...........why u on this if u aint got BPRG shares. Not that i care..........i get fedup with bawbags on threads trying to ruin them. You seem to be taking up half this thread, its pathetic. And what u type is drivvle anyway.

I'm trying to be polite

You go for it , no need to hold back ... free country.

And what makes your opinion of these so superior to mine ?

i might have known u would respond and no one else has posted anything.

It aint a free country by the way.........u r in a police state if u r in the UK. Dont u realise that yet as Emperor Blair has all his boys watching u.

U always seem to infer something else from someones comments. U seem to have a chip on your shoulder in life.
Maybe u should see a psychiatrist. If u can afford one. Anyway u r one sad prick sitting here all day posting meaningless posts

More power to your elbow DIL, you have em on the run.
Agree with you 100%, BPRG has made many people poorer.
Cheers.

Well if you feel its that bad in this country why not fcuk off somewhere nicer ... if you can afford it scotty .

porky

Surely people have the right to lose their "own" money in peace, everyone knows this is a high risk stock but with the risk comes the potential of high returns.

I know every thread has someone of dils ilk, a know it all who tells everyone the stock is a dog and is destined to fail; why can't these people let people make their own mistakes?

If it's done to counteract ramping then it may be fair enough but when it's done out of sheer spite then it's pointless.

ps I bet their were some dils around when the petrol engine was invented, "it'll never work, steam does a perfectly good job"!

hypocrisy at its very best Shamoaner

sham ... which bit is out of spite ???

Most of my post address the bullsh*t posted by rampers , the same bullsh*t that has been spouted time and time again all the way down.

Don't post crap and I won't respond.

Dil, lol

Oi rampers ... results are out.

Market showing what it thinks.

BioProgress PLC
27 September 2005

27 September 2005

BioProgress plc
('BioProgress' or 'the Company')

(AIM: BPRG; NASDAQ: BPRG)


Interim Results for the six months to 30 June 2005


I would like to start this interim report by welcoming our new non executive
Chairman Peter Ibbetson who joined the Board on the 29 July 2005. Peter has a
wealth of experience across a number of sectors and his depth of banking and
financial relationships will be of great future value to BioProgress. We are
delighted that Peter has joined the team and look forward to working closely
with him.


As previously reported, 2005 has been a turbulent year with a number of
significant challenges for BioProgress. On 13 April 2005 the Board reported
that trading levels from BioTec Films would be below expectations. The Board
also embarked upon a strategic review of the business due to unexpected and
excessive increases in overheads and other cost structures. Although remedial
action has been taken, both during and since the conclusion of the review, the
benefits of these initiatives will take effect after the period to which this
statement relates. The management and structural changes took place in May and
June 2005 and consequently have limited impact upon the interim performance.


Financial performance


The first six months trading resulted in an operating half year loss of 6.23
million compared with a loss of 3.97 million for the same period in 2004. This
substantial increase was due to a number of factors including:

Significant monthly trading losses from the Company's trading subsidiary
BioTec Films Inc.;

Increased costs associated with inappropriate capital expenditure
commitments entered into by the Company; and

Growth in non-productive overheads across the Company's operations.



A proportion of these increased costs also related to implementation of the
LOCUM strategy and non-trading related investment activity carried out by the
Company. Both these activities have now been stopped.



Other non-trading costs have also impacted the Company's financial performance.
These include:

Legal and other professional costs principally associated with the
continuation of various litigation proceedings undertaken by the Company;
and

Consultancy arrangements.



In both these cases substantial reductions have been implemented which will
impact during the second half of the current financial year. The new management
team has taken steps to settle legal proceedings where possible but not in
situations where the asset base of the Company has been impinged upon.



Cash burn for the period under review increased significantly, a function of the
above factors, as well as an increase in general expenses. The implied monthly
burn rate peaked at approximately 1 million per month during this period. With
the new financial controls and restructuring initiatives in place this figure
currently runs at an operational rate of approximately 200,000 per month and is
expected to continue falling. This, despite the historic excessive spending
levels, left the Company with a relatively strong current cash position at the
half year of approximately 9 million.



Operational performance



Progress during the period under review was slower than anticipated. The
Company's new management team continues to review the commercial viability of
previous arrangements and expects to conclude this process within the next
trading year.



Worthy of note, however, was the delivery of the first NROBE machine for powder
encapsulation to our strategic partner FMC Biopolymer, a business unit of the
FMC Corporation.



The development of the Company's first TABWRAP machine is proceeding on course
for demonstration at the Madrid cPHI conference despite issues relating to its
development earlier in the year. Integration of BioTec's development team with
the technical team within Cambridgeshire, carried out post the period under
review has yielded positive results within a more project management style
structure. We expect this to impact positively upon the Company's performance
towards the end of the financial year and the next trading year onwards.



The Company has continued to develop new relationships with prospective
commercial partners; a drive which was increased after the period under review.
Most of these developments relate to sensitive commercial developments and
consequently the Company has committed to strict confidentiality undertakings in
respect of such developments. Nevertheless, these developments present
significant opportunities for the Company and continued validation of the
strength and robustness of its intellectual property asset base.



Post results events



As stated at our Annual General Meeting ('AGM'), despite the turbulence of the
period under review the quick actions taken and remedial measures implemented by
management have enabled a rapid restructuring with the result that the Company
remains in a relatively strong position both commercially and financially. Some
of the steps taken have included:

Restructuring of the operations of the Company to a matrix project
management approach with fully costed resource centres applied in a
structured way for the creation of a solutions led approach to partner and
own generated projects;

Implementation of strict and effective financial and operational controls;

Separation of developmental projects with full project analysis plans;

Head count reduction of approximately 50% in the UK and 30% in the US;

Replacement of a number of our professional advisors and consultants,
which the Board continue to monitor on a 'value added' basis; and

Strengthening of the technical, scientific and developmental resources
within the Company and realignment of resources from non value generating to
value generating areas.



These measures have created new dynamism within the Company and provided a more
transparent infrastructure in which the Company's operations can be managed
effectively.



In light of the changing nature of the Company and increased activity within
Ghaliston, Anthony Fabrizi has decided to resign from the Board. We wish him
well and every success for the future. The Board expects to announce an
additional non-executive director appointment shortly to compliment our skills
and needs as a business.



I would like to thank my fellow directors and colleagues for their support
during this period and for the enthusiasm shown by the team in their
determination to remove the obstacles to growth and working with me and the new
management team in redirecting and positioning the Company for growth.



The Board remains committed to the Company's strategy, outlined at the AGM and
optimistic as to the future of the Company. We believe that the restructuring
measures implemented have created a more solid platform to efficiently realise
the Company's growth plans.


Richard Trevillion

Chief Executive Officer


Enquiries:

BioProgress plc 01354 655674
Richard Trevillion, Chief Executive Officer
Dan Farrow, Finance Director

College Hill 020 7457 2020
Adrian Duffield/Corinna Dorward



Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. To the extent that this announcement contains certain
'forward-looking statements' within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies. These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances. Actual results may vary materially from the
expectations contained in the forward-looking statements. The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation. Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company's filings with the
Securities and Exchange Commission. The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice. The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law. Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.

shamona - 22 Sep 2005 15:50 - 2047 of 2060
Nice recovery today, bodes well for the coming days.

Only 4 trading days till interims now, should get a run up to them.

And then a nice run down, what a load of crap this company is!

Dil,

You are good value I'll give you that :)

Now you know I am not a ramper and have been out of this for some while (last sale at 68p) but seeing as the market has since put these down to 27p, are you still saying they are 27p too expensive? :)

If you do, I think that makes you no better than the "rampers" on the way up who see a limitless sky ahead. So, my question to you Dil is, do you have a serious answer to the question - when would you buy these from a pure trading point of view? By that I mean, are you relying on the charts and if so will you only buy when they have safely cleared 160p? Or are you truly besotted by the share in a reverse sense.

If your answer is "never, they are a crock of sh*t" then I'll draw my own conclusions, but I am genuinely interested in a bear's view :)

Oh, did I not say? I've bought these back today at just under 28p. The reason is because all the "derampers" (shall we call them that?) are focussing on the historical results and past management. In my opinion, I am buying a new company, new management, new strategy. Sure it is a risk, like all tech or bio shares, but it's a damn sight less of a risk than the poor boobies who mortgaged their houses and paid 150p during the euphoria.

Anyway, I like to be open with my purchases and sales, no abuse necessary :)

It seems to have gone very quiet on here. Now there is no need to speculate about how crap the figures are/were going to be I'd have expected all those knowledgeable rampers to be out in force.

Perhaps the truth is not as palatable as was thought it was going to be.

Might be worth picking a few of these up for a recovery when they get under 20p...

[EDIT - our posts crossed Bones - my comments weren't aimed at you - just in case you thought they were]